NYSEHealth CareHealthcare PlansSnapshot 2026-07-23
Reading MOH? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a durable compounder with a focus on healthcare. The current thesis state is stable, supported by recent earnings beats and a reaffirmation of guidance, although there are risks tied to sector performance.
The market appears to have priced in a low expectations gap, suggesting that investors are cautious but not overly pessimistic. Valuation is considered cheap compared to peers, indicating room for potential appreciation if fundamentals improve.
Management has shown a robust focus on maintaining guidance for both revenue and earnings, despite some recent declines. However, there is elevated risk due to the potential for future earnings misses, which could impact credibility.
The key factors for MOH's future performance include the ability to maintain guidance amid sector trends and the performance of major healthcare peers like UNH, CVS, and ELV. Any changes in their earnings results could significantly influence MOH's trajectory.
Overall, MOH's position is supported by strong fundamentals and sector momentum, but it faces risks that could impact its credibility. Not investment advice.
The most important moves since the prior daily snapshot.
Company momentum rose by 20.0 points (from 26.0 to 46.0) after fresh earnings.
Yes, our read has weakened. The latest earnings beat and reaffirmed guidance are positive signs. However, a sharp drop in the stock may indicate a repricing of the thesis. Additionally, the planned exit from the Medicare Advantage Part D product could impact future growth.
as of 2026-07-23
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This shows earnings may recover after a big drop in Q1 2026.
Confirms:Q2 adjusted earnings reported at or above $2.35 per diluted share.
Disproves:Q2 adjusted earnings fall below $2.35 per diluted share.
Why it matters: A big drop in premium revenue may mean losing members and facing cost issues.
Confirms:Q3 premium revenue down more than 5% year over year from approximately $10.2 billion.
Disproves:Q3 premium revenue declines less than 5% year over year or stabilizes.
Why it matters: An EPS below this level may show profit problems and affect investor feelings.
Confirms:Q3 adjusted EPS reported below $1.50.
Disproves:Q3 adjusted EPS reported at or above $1.50.
Why it matters: This event may give clues about long-term financial goals and plans.
Confirms one read:Good news about long-term goals. These goals match what the market expects.
Confirms the other:Bad news or unclear plans may make investors nervous.
Why it matters: This guidance shows Molina can keep revenue steady even with market challenges.
Confirms one read:Molina says it expects to make about $42 billion in premium revenue for 2026.
Confirms the other:Molina now expects to make less than $42 billion in premium revenue for 2026.
Why it matters: This guidance shows Molina believes future earnings will improve. It changes how the market sees them.
Confirms:Molina says adjusted earnings guidance stays the same in the next earnings report.
Disproves:Molina cuts its earnings guidance for the next report.
Why it matters: A higher MCR shows rising medical costs. This could hurt margins and earnings.
Confirms:Medicaid MCR is over 93% in Q3. This shows rising cost pressures.
Disproves:Medicaid MCR is below 93% in Q3. This suggests good cost management.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Why it matters: A good contract could help Molina's market position. It may also increase revenue.
Confirms:The Illinois Medicaid contract will start on January 1, 2027.
Disproves:There are delays or problems with the Illinois Medicaid contract.
